Neural Cell Adhesion Molecule (CD56)–Positive Acute Myelogenous Leukemia and Myelodysplastic and Myeloproliferative Syndromes

Mann, Karen P.; DeCastro, Carlos M.; Liu, Jane; Moore, Joseph O.; Bigner, Sandra H.; Traweek, S. Thomas

doi:10.1093/ajcp/107.6.653

Cited by 37 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression of monocyte-associated markers CD4, CD14, CD11b, CD64 and CD56 is common. [212][213][214] Relatively frequent expression of B cell markers has been reported 170 but other studies have not confirmed this finding. 213,215 Most cases of AML with 11q23 alterations aberrantly express NG2 homologue, similarly to the ALL cases with MLL rearrangements (see section ALL with rearrangements of MLL for details on NG2).…”

Section: Abnormalities Of Mll Genementioning

confidence: 94%

Antigen expression patterns reflecting genotype of acute leukemias

2002

View full text Add to dashboard Cite

show abstract

Section: Abnormalities Of Mll Genementioning

confidence: 94%

Antigen expression patterns reflecting genotype of acute leukemias

2002

View full text Add to dashboard Cite

show abstract

“…Until recently, the immunophenotype of mature, nonblast myeloid cells (NBMCs) in MDS was largely ignored [7,9,11,16,17].…”

Section: Introductionmentioning

confidence: 99%

Evidence for expression of early myeloid antigens in mature, non‐blast myeloid cells in myelodysplasia

Schultz

Akker

et al. 2003

American J Hematol

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders with frequent cytogenetic abnormalities. They can arise de novo or be related to therapy. Although blasts in MDS have been studied extensively, there is little information available on the mature, non-blast myeloid cells (NBMCs). We used a retrospective case-control study design. NBMC populations in MDS (48 cases) and in tumor-free control (12 cases) bone marrow samples were analyzed using multiparameter flow cytometry for mean side scatter (SSC) channel number and for expression of aberrant cell surface antigens. MDS cases were stratified on the basis of cytogenetic abnormalities. We report that NBMCs in MDS with normal karyotype expressed significantly higher HLA-DR than controls (P = 0.034). NBMCs in MDS cases with cytogenetic abnormalities and with ≥5% marrow blasts, compared with controls, had significantly higher CD34 and higher HLA-DR but lower CD10 and lower SSC mean channel number. CD34 expression in NBMCs was significantly greater in therapy-related MDS compared with de novo MDS (P = 0.01), although the presence of cytogenetic abnormalities was not different (P > 0.05). These data suggest that bone marrow, mature, NBMCs have phenotypic changes in MDS that are not seen in normal controls. Am. J. Hematol. 74:9-16, 2003.

show abstract

“…Aberrant expression of CD56 was previously reported in myeloblasts [22,23] and mature granulocytes in MDS [4, Data are median (range), except positive rate (positive case/total cases with available data). Statistical significance analysis was performed for comparison of non-clonal disorders vs other groups and MDS vs leukemia.…”

Section: Immunophenotypic Features Of Blast Gatingmentioning

confidence: 99%